Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares OutstandingShares OutstandingShares Repurchased
Ratios

Pharma-Bio Serv (PBSV) Gross Profit (2016 - 2026)

Pharma-Bio Serv filings provide 16 years of Gross Profit readings, the most recent being $722374.0 for Q1 2026.

  • On a quarterly basis, Gross Profit fell 5.95% to $722374.0 in Q1 2026 year-over-year; TTM through Jan 2026 was $2.9 million, a 4.21% increase, with the full-year FY2025 number at $2.9 million, up 15.66% from a year prior.
  • Gross Profit hit $722374.0 in Q1 2026 for Pharma-Bio Serv, down from $748935.0 in the prior quarter.
  • In the past five years, Gross Profit ranged from a high of $1.6 million in Q3 2023 to a low of $535609.0 in Q1 2024.
  • Median Gross Profit over the past 5 years was $818726.0 (2025), compared with a mean of $946841.4.
  • Biggest five-year swings in Gross Profit: plummeted 59.01% in 2024 and later skyrocketed 43.41% in 2025.
  • Pharma-Bio Serv's Gross Profit stood at $1.1 million in 2022, then dropped by 16.13% to $929805.0 in 2023, then fell by 21.86% to $726570.0 in 2024, then rose by 3.08% to $748935.0 in 2025, then dropped by 3.55% to $722374.0 in 2026.
  • The last three reported values for Gross Profit were $722374.0 (Q1 2026), $748935.0 (Q4 2025), and $574262.0 (Q3 2025) per Business Quant data.